Overview
- In the overall study population, vepdegestrant achieved a median progression-free survival of 3.8 months compared with 3.6 months for Faslodex.
- Among patients with ESR1 mutations, the oral PROTAC ER degrader extended progression-free survival by five months versus about two months for injectable Faslodex.
- Vepdegestrant harnesses the body’s protein disposal system to specifically target and degrade estrogen receptors that drive tumor growth.
- Arvinas has opted not to proceed with two additional late-stage trials of the drug following the detailed ASCO data.
- The findings were presented in Chicago at the American Society of Clinical Oncology’s annual meeting and published in The New England Journal of Medicine.